Related references
Note: Only part of the references are listed.Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
G. Freyer et al.
BRITISH JOURNAL OF CANCER (2012)
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I. Diaz-Padilla et al.
BRITISH JOURNAL OF CANCER (2012)
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
Jonathan W. Riess et al.
CANCER INVESTIGATION (2012)
A preclinical and clinical review of aflibercept for the management of cancer
Andrew Gaya et al.
CANCER TREATMENT REVIEWS (2012)
Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Nicolas Isambert et al.
CLINICAL CANCER RESEARCH (2012)
Safety Profile and Tolerability of Antiangiogenic Agents in Non-Small-Cell Lung Cancer
Shirish M. Gadgeel
CLINICAL LUNG CANCER (2012)
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
Rodryg Ramlau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cervical Adenocarcinoma in a Patient With Lynch Syndrome, Muir-Torre Variant
Navya Nair et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis
Amna Sher et al.
ACTA ONCOLOGICA (2011)
Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy
Basel Sitohy et al.
CANCER RESEARCH (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors
Wiem Lassoued et al.
CANCER BIOLOGY & THERAPY (2010)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew et al.
CLINICAL CANCER RESEARCH (2010)
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Grzegorz Korpanty et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
A. Craig Lockhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hunting and Trapping the Vascular Endothelial Growth Factor
Afshin Dowlati
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Suzanne E. Dahlberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)
Natasha B. Leighl et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
CLINICAL LUNG CANCER (2009)
Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs
M. A. Marinella et al.
INTERNAL MEDICINE JOURNAL (2009)
Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features
W. S. Bartynski
AMERICAN JOURNAL OF NEURORADIOLOGY (2008)
Clinical spectrum of reversible posterior leukoencephalopathy syndrome
Vivien H. Lee et al.
ARCHIVES OF NEUROLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reversible Posterior Leukoencephalopathy Syndrome in Cancer
Christopher Vaughn et al.
CURRENT ONCOLOGY REPORTS (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Betty Y. Y. Tam et al.
NATURE MEDICINE (2006)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
